Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Pharmacy leaders say 2026 is shaping up to be a year defined by financial volatility, regulatory pressure and workforce strain — all intensified by upcoming federal drug pricing reforms. Across ...

At Crain's Hospital CEO Breakfast, executives said Medicaid spending cuts, combined with expired ACA tax credits, threaten the quality and availability of care across the region.

Callen Lorde boosts HIV prevention access by integrating insurance verification and prior authorizations into EHR workflows, improving care coordination.

Formerly Ohio’s lieutenant governor, he was appointed to fill the seat vacated by JD Vance when Vance assumed the vice ...

Peter Navarro‘s appeal of his contempt of Congress conviction may seem, to some, unnecessary. Last year, fresh out of prison ...

Calling the looming impact of cuts to health care contained in the One Big Beautiful Bill and the expected expiration of tax credits from the Affordable Care Act “humongous,” the leader of the ...

Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...

As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.